CY2388B1 - Rate-controlled transdermal administration of risperidone. - Google Patents

Rate-controlled transdermal administration of risperidone.

Info

Publication number
CY2388B1
CY2388B1 CY0300076A CY0300076A CY2388B1 CY 2388 B1 CY2388 B1 CY 2388B1 CY 0300076 A CY0300076 A CY 0300076A CY 0300076 A CY0300076 A CY 0300076A CY 2388 B1 CY2388 B1 CY 2388B1
Authority
CY
Cyprus
Prior art keywords
risperidone
rate
transdermal administration
controlled transdermal
controlled
Prior art date
Application number
CY0300076A
Other languages
English (en)
Inventor
Jean Louis Mesens
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CY2388B1 publication Critical patent/CY2388B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY0300076A 1995-04-06 2003-11-04 Rate-controlled transdermal administration of risperidone. CY2388B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95200867 1995-04-06

Publications (1)

Publication Number Publication Date
CY2388B1 true CY2388B1 (en) 2004-09-10

Family

ID=8220172

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0300076A CY2388B1 (en) 1995-04-06 2003-11-04 Rate-controlled transdermal administration of risperidone.

Country Status (17)

Country Link
EP (1) EP0879051B9 (pt)
JP (1) JPH11503138A (pt)
KR (1) KR100437672B1 (pt)
AR (1) AR003413A1 (pt)
AT (1) ATE242631T1 (pt)
CA (1) CA2214420A1 (pt)
CY (1) CY2388B1 (pt)
DE (1) DE69628672T2 (pt)
DK (1) DK0879051T3 (pt)
ES (1) ES2201176T3 (pt)
HK (1) HK1015681A1 (pt)
HR (1) HRP960154A2 (pt)
IL (1) IL117809A (pt)
PT (1) PT879051E (pt)
TW (1) TW592729B (pt)
WO (1) WO1996031201A1 (pt)
ZA (1) ZA962752B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042412B4 (de) * 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
ATE413166T1 (de) 2004-11-22 2008-11-15 Hisamitsu Pharmaceutical Co Transdermales pflaster enthaltend einen schmelzpunktsenkenden hilfsstoff
WO2006093139A1 (ja) * 2005-02-28 2006-09-08 Hisamitsu Pharmaceutical Co., Inc. 経皮吸収製剤
WO2007035942A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal risperidone delivery system
KR101390012B1 (ko) 2006-06-09 2014-04-29 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규한 테이프 제제
DE102007006244B4 (de) 2007-02-08 2012-03-15 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System zur Verabreichung wasserlöslicher Wirkstoffe
EP2230911A4 (en) * 2007-12-21 2013-07-03 Zars Pharma Inc STAMPS, FORMULATIONS, AND RELATED METHODS FOR THE TRANSDERMAL DELIVERY OF ALPRAZOLAM AND OTHER MEDICAMENTS
US20120052112A1 (en) * 2009-02-24 2012-03-01 Hisamitsu Pharmaceutical Co., Inc. Risperidone-containing transdermal preparation and adhesive patch using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US4710191A (en) * 1985-12-16 1987-12-01 Jonergin, Inc. Therapeutic device for the administration of medicaments
US4938759A (en) * 1986-09-02 1990-07-03 Alza Corporation Transdermal delivery device having a rate controlling adhesive
US5788983A (en) * 1989-04-03 1998-08-04 Rutgers, The State University Of New Jersey Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes
ATE135216T1 (de) * 1989-08-21 1996-03-15 Beth Israel Hospital Verwendung von spiperone-derivate zur immunosuppression

Also Published As

Publication number Publication date
IL117809A (en) 2000-10-31
TW592729B (en) 2004-06-21
PT879051E (pt) 2003-10-31
EP0879051A1 (en) 1998-11-25
DK0879051T3 (da) 2003-09-29
CA2214420A1 (en) 1996-10-10
WO1996031201A1 (en) 1996-10-10
ATE242631T1 (de) 2003-06-15
DE69628672D1 (de) 2003-07-17
EP0879051B9 (en) 2004-03-03
EP0879051B1 (en) 2003-06-11
JPH11503138A (ja) 1999-03-23
KR100437672B1 (ko) 2004-09-10
AR003413A1 (es) 1998-08-05
DE69628672T2 (de) 2004-04-29
AU5149296A (en) 1996-10-23
IL117809A0 (en) 1996-08-04
HK1015681A1 (en) 1999-10-22
AU696789B2 (en) 1998-09-17
ZA962752B (en) 1997-10-06
HRP960154A2 (en) 1997-08-31
ES2201176T3 (es) 2004-03-16

Similar Documents

Publication Publication Date Title
AU7070596A (en) Transdermal administration of olanzapine
ZA928011B (en) Transdermal administration of melatonin.
ZA962536B (en) Pharmaceutical composition for transdermal administration.
PL328399A1 (en) Drug administration aid
AU5397996A (en) Iontophoretic transdermal system for the administration of at least two substances
AU5263496A (en) Targeted catheter drug administration
EP0621769A4 (en) TRANSDERMAL ADMINISTRATION OF BENZODIAZEPINES FOR SHORT OR INTERMEDIATE HALF-LIVES.
AU6534894A (en) Drug administration system
HUP9901437A3 (en) Pharmaceutical formulation, containing amoxycillin and clavulanate
EP0581587A3 (en) Base material for transdermal administration.
AU2782592A (en) Thermal enhancement of transdermal drug administration
HK1022432A1 (en) Administration of histamine for therapeutic purposes.
AU6934691A (en) Transdermal administration of zwitterionic drugs
ZA962752B (en) Rate-controlled transdermal administration of risperidone.
HUP0001263A3 (en) Methods of therapeutic administration of anti-cd4ol compounds
AU703235B2 (en) 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives having PDE IV and cytokine inhibiting activity
GB9508823D0 (en) Drug Derivatives
ZA966842B (en) Transdermal administration of vorozole.
ZA96796B (en) Transdermal formulation.
GB9601186D0 (en) Administration of Drugs
AU6617798A (en) Extensible transdermal therapeutic system
GB9524942D0 (en) Drug therapy
AU6800994A (en) Neuro-muscular stimulator
ZA966083B (en) Agent for transdermal administration containing esters of 13-ethyl-17ß-hydroxy-11-methylene-18,19-dinor-17Ó-pregn-4-en-20-yn-3-one.
DE29501910U1 (de) Transdermales therapeutisches den Wirkstoff Dimethisoquin enthaltendes System